A phase I, open-label, multi-center dose-finding and expansion study to investigate the safety, tolerability, and preliminary efficacy of CR-001 (5-FU-miR-15a) in patients with acute myeloid leukemia

ABSTRACT Purpose Evaluating the safety and tolerability of 5-FU-miR-15a (CR-001) in adults with relapsed or refractory acute myeloid leukemia (R/R AML) in a phase I dose-escalation study (EudraCT number: 2021-006332-46). Patients and Methods A standard 3+3 dose-escalation study design was employed. Patients received intravenous (IV) administrations of the synthetic double-stranded mimic of miR-15a (miRNA) CR-001 of 7.5 mg, 11.25 mg, 15 mg and 18.75 mg/administration, weekly dosing. Each patient was dosed on a single dose level. The formulation included a fixed dose of GMP-grade linear polyethyleneimine (PEI; α-Methyl-ω-hydroxy-poly[(iminioethylene)chloride]; Poly[imino(1,2-ethanediyl)]; CAS Number 26913-06-4; EC Number 608-018-6) as the excipient: 15 mg of PEI with 7.5 mg CR-001, and 20 mg of PEI with all higher dose levels. Glucose was added to stabilize the miRNA/PEI complexes. Biomarker analysis was performed using mass cytometry (CyTOF) on peripheral blood and bone marrow samples to quantify surface and intracellular protein expression at the single-cell level. Results A total of 11 patients with R/R AML (median age: 74 years; all classified as adverse risk per ELN 2022) received a cumulative 66 intravenous doses of CR-001 (range: 1–16 doses; median: 5) across the four dose levels. The treatment was well-tolerated. One patient demonstrated a partial clinical response, with resolution of extramedullary pericardial AML after four doses. Among the 10 evaluable patients, six achieved stable disease (SD) according to ELN criteria after four infusions. Single-cell profiling mass cytometry revealed molecular activity of CR-001 on known targets of miR-15a (e.g., BMI1, WEE1 and MCL-1) beginning at the lowest dose level (7.5 mg). Concurrently, an increase in BAX, a pro-apoptotic marker, was observed following treatment. Conclusions CR-001 was well tolerated and demonstrated biological activity as evidenced by target modulation and disease stabilization in R/R AML patients. Biological activity was observed starting at the lowest dose level (7.5 mg/administration), with initial signs of clinical efficacy at 11.25 mg per administration. This trial was closed prematurely due to funding constraints, however, based on these findings further development is warranted, possibly in therapy combinations.